ASP 5094

Drug Profile

ASP 5094

Alternative Names: ASP5094

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Antirheumatics
  • Mechanism of Action Integrin alpha9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis

Most Recent Events

  • 11 Nov 2016 Safety and pharmacokinetics results from the phase I trial in Rheumatoid arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR-ARHP-2016)
  • 11 Nov 2016 Astella Pharma initiates a phase I trial for Rheumatoid arthritis (In volunteers) in USA (IV) before November 2016
  • 01 Feb 2016 Phase-I clinical trials in Rheumatoid arthritis in USA (IV) (NCT02698657)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top